#USA #Boston #ASCO 2025 #AVEO Oncology #Tivozanib

AVEO Oncology Highlights Tivozanib at ASCO GU 2025

AVEO Oncology, a prominent biopharmaceutical company under LG Chem, showcased significant new findings regarding Tivozanib at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) meeting. Tivozanib, a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, aims to enhance the lives of cancer patients by effectively targeting the VEGF pathway.

The Research Presentation

During the conference, AVEO presented two important posters detailing recent analyses from various studies conducted with Tivozanib. The first poster, titled "Integrated efficacy and safety exposure response (ER) analysis of Tivozanib for the treatment of renal cell carcinoma (RCC)," discussed data from three Phase 3 trials: TIVO-1, TIVO-3, and TiNivo-2. This exploratory analysis evaluated the relationship between the effectiveness and safety of Tivozanib and its patient exposure levels, aiming to understand the link between drug dosage, progression-free survival (PFS), and other patient outcomes in metastatic RCC.

Data revealed a strong correlation between higher exposure to Tivozanib and improved PFS. Notably, both standard and low doses of Tivozanib resulted in similar rates of hypertension, suggesting good tolerability in the studied populations.

In the second poster titled "Patient-reported outcomes (PROs) for Tivozanib + Nivolumab vs Tivozanib monotherapy in patients with RCC following immunotherapy," AVEO showcased findings from the TiNivo-2 study. This Phase 3 trial was designed to evaluate the efficacy and safety of Tivozanib combined with the PD-1 inhibitor Nivolumab after patients had progressed on prior treatments. While the addition of Nivolumab did not meet its primary endpoint, Tivozanib monotherapy demonstrated clinically meaningful outcomes, particularly as a second-line treatment following immune checkpoint inhibitor therapy.

Using validated questionnaires such as the Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index-Disease-Related Symptoms (FKSI-DRS) and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, the study found that Tivozanib showed stability in patient-reported health outcomes over time, with better outcomes in patients receiving Tivozanib as second-line treatment compared to those on third-line therapy.

Broader Implications

Michael Bailey, CEO of AVEO, expressed excitement about sharing these findings with the oncology community, building upon the robust clinical data established for Tivozanib. The outcomes reflect AVEO's commitment to advancing care for patients with advanced RCC, emphasizing the importance of understanding both clinical efficacy and patient-reported outcomes.

AVEO's work with Tivozanib is especially significant given the ongoing challenges posed by RCC treatment options, particularly after several lines of therapy. With FDA approval achieved in 2021 and previously authorized in various international territories, Tivozanib remains a cornerstone in AVEO's strategy to overcome treatment failures in relapsing cases.

AVEO's Future Goals

Looking ahead, AVEO Oncology plans to continue its research and development activities, focusing not only on Tivozanib's applications in RCC but also exploring novel combinations with immunotherapies and developing strategies tailored to the needs of cancer patients.

As the company embraces its role as a subsidiary of LG Chem, it remains dedicated to delivering innovative solutions that enhance the quality of life for cancer patients globally.

For detailed information on the findings from ASCO GU 2025 and Tivozanib, interested parties can refer to AVEO's official communications and the presiding medical literature.

Conclusion

AVEO Oncology continues to be a key player in cancer therapy advancement, as demonstrated at ASCO GU 2025, reinforcing its commitment to improving patient outcomes and addressing critical needs in oncology care.